251 related articles for article (PubMed ID: 1397716)
1. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
[TBL] [Abstract][Full Text] [Related]
2. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
3. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Akanji AO; Osifo E; Kirk M; Hockaday TD
Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
[TBL] [Abstract][Full Text] [Related]
4. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Berrish TS; Elliott C; Cooper BG; Reed JW; Orskov H; Alberti KG; Walker M
Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
[TBL] [Abstract][Full Text] [Related]
5. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Piatti PM; Monti LD; Davis SN; Conti M; Brown MD; Pozza G; Alberti KG
Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
[TBL] [Abstract][Full Text] [Related]
6. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H
J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
[TBL] [Abstract][Full Text] [Related]
7. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
8. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
Fulcher GR; Walker M; Catalano C; Farrer M; Alberti KG
Clin Sci (Lond); 1992 May; 82(5):565-71. PubMed ID: 1317767
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
10. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
11. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Puhakainen I; Yki-Järvinen H
Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
[TBL] [Abstract][Full Text] [Related]
13. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
Walker M; Agius L; Orskov H; Alberti KG
Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
[TBL] [Abstract][Full Text] [Related]
14. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
[TBL] [Abstract][Full Text] [Related]
15. Contribution of obesity to defects of intracellular glucose metabolism in NIDDM.
Chung JW; Suh KI; Joyce M; Ditzler T; Henry RR
Diabetes Care; 1995 May; 18(5):666-73. PubMed ID: 8586004
[TBL] [Abstract][Full Text] [Related]
16. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
17. Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM.
Féry F; Balasse EO
Diabetes; 1994 Dec; 43(12):1418-25. PubMed ID: 7958493
[TBL] [Abstract][Full Text] [Related]
18. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
20. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
